Novel mutational and genetic studies in MDS, myelodysplastic syndrome

Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which might in the future translate into clinical benefits. One involves a significantly sensitive and sophisticated prognostic scoring system; another involves gene expression in MDS that may allow the classification of patients according to prognosis.

Keywords:
Myelodysplastic Syndrome (MDS)
Prof. Valeria Santini
University of Florence Medical School
Genetic studies in MDS
EHA19